- Home
- Publications
- Publication Search
- Publication Details
Title
Trastuzumab in the Treatment of Breast Cancer
Authors
Keywords
Breast Cancer, Trastuzumab, Human Epidermal Growth Factor Receptor, Advanced Breast Cancer, Lapatinib
Journal
BIODRUGS
Volume 30, Issue 2, Pages 75-86
Publisher
Springer Nature
Online
2016-02-19
DOI
10.1007/s40259-016-0162-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain
- (2015) Ajay Patil et al. CANCER LETTERS
- Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice
- (2015) S. Antolín-Novoa et al. Clinical & Translational Oncology
- Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
- (2015) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
- (2015) Ciara C. O'Sullivan et al. JOURNAL OF CLINICAL ONCOLOGY
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
- (2014) F. Cardoso et al. ANNALS OF ONCOLOGY
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
- (2014) X. Pivot et al. ANNALS OF ONCOLOGY
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Features of breast cancer in developing countries, examples from North-Africa
- (2014) Marilys Corbex et al. EUROPEAN JOURNAL OF CANCER
- Subcutaneous Administration of Monoclonal Antibodies in Oncology
- (2014) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study
- (2014) Jian Xue et al. Journal of Breast Cancer
- Safety and Tolerability of Docetaxel, Cyclophosphamide, and Trastuzumab Compared to Standard Trastuzumab-Based Chemotherapy Regimens for Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2014) Potjana Jitawatanarat et al. Journal of Breast Cancer
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials
- (2014) Feng Du et al. MEDICAL ONCOLOGY
- Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients
- (2014) Sahil Ahmad et al. Scientific Reports
- Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?
- (2014) J-R Azanza et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) E. Senkus et al. ANNALS OF ONCOLOGY
- Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
- (2013) Ana Catarina Pinto et al. BREAST
- Biological therapies in breast cancer: Common toxicities and management strategies
- (2013) Romualdo Barroso-Sousa et al. BREAST
- Co-targeting estrogen receptor and HER2 pathways in breast cancer
- (2013) Arjun Mehta et al. BREAST
- Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis
- (2013) Flora Zagouri et al. BREAST CANCER RESEARCH AND TREATMENT
- Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males
- (2013) Chris J. Wynne et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications
- (2013) Brent N. Rexer et al. CANCER RESEARCH
- Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
- (2013) Pradip De et al. CANCER TREATMENT REVIEWS
- Trastuzumab in small tumours and in elderly women
- (2013) Joan Albanell et al. CANCER TREATMENT REVIEWS
- SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013
- (2013) S. Del Barco et al. Clinical & Translational Oncology
- Trastuzumab Emtansine: First Global Approval
- (2013) Anita Ballantyne et al. DRUGS
- Targeted therapy for HER2 positive breast cancer
- (2013) Jason A Incorvati et al. Journal of Hematology & Oncology
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
- (2013) Aman U Buzdar et al. LANCET ONCOLOGY
- Le trastuzumab dans le traitement adjuvant du cancer du sein
- (2013) Nabil Ismaili et al. PRESSE MEDICALE
- The war on cancer: are we winning?
- (2013) M. J. Duffy TUMOR BIOLOGY
- Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
- (2013) Gabriel Tinoco et al. Journal of Cancer
- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- Optimal Management of Brain Metastases from Breast Cancer
- (2012) Rupert Bartsch et al. CNS DRUGS
- The global breast cancer burden
- (2012) John R Benson et al. Future Oncology
- US Food and Drug Administration Approval Overview in Metastatic Breast Cancer
- (2012) Patricia Cortazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
- (2012) Chris Wynne et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis
- (2011) Michal Mego et al. BREAST
- Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab
- (2011) Mafalda Oliveira et al. BREAST CANCER RESEARCH AND TREATMENT
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better
- (2011) Fausto Petrelli et al. MEDICAL ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†
- (2010) Karly P. Garnock-Jones et al. BIODRUGS
- Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
- (2010) Anna Emde et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer
- (2009) C. Ferrario et al. ANNALS OF ONCOLOGY
- Breast cancer as a global health concern
- (2009) Steven S. Coughlin et al. Cancer Epidemiology
- Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab
- (2008) Mariantonietta Colozza et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trastuzumab
- (2008) Kate McKeage et al. PHARMACOECONOMICS
- Herceptin and breast cancer: An overview for surgeons
- (2008) N. Patani et al. SURGICAL ONCOLOGY-OXFORD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now